Good News for Celgene's Pipeline - Analyst Blog

By
A A A

Celgene Corporation ( CELG ) announced recently that its pipeline candidate apremilast (30 mg, twice daily) has fared well in a phase II study (BCT-001). The study evaluated apremilast in patients suffering from Behçet's disease, a chronic inflammatory disorder. The disease, whose cause is not known, often leads to ulcers in the mouth and genitals. Celgene presented encouraging results at the annual meeting of the European Congress of Rheumatology held in Spain.

Celgene announced that apremilast was successful in achieving the primary endpoint (the mean number of oral ulcers at week 12) as well as secondary endpoints of the multi-center, randomized, placebo-controlled, double-blind, parallel-group study. Successful development and subsequent commercialization of apremilast for this rare (orphan) disease would be highly appreciated by the patients since the disease currently has no approved therapies in the US or Europe. Celgene is currently evaluating opportunities to seek approval of apremilast in the Behçet's disease indication in multiple countries.

Celgene is also developing apremilast for other indications including psoriatic arthritis, and psoriasis. The company recently presented encouraging data on the candidate in the psoriatic arthritis indication. Earlier this year, Celgene made regulatory submissions for the approval of apremilast (psoriatic arthritis) in the US and Canada. Approvals of apremilast in the US and Canada for the psoriasis indication are expected to be sought in the latter half of the year. Moreover, the biopharmaceutical company intends to seek European approval for apremilast for the psoriatic arthritis and psoriasis indications on a combined basis in the second half of the year.

Celgene carries a Zacks Rank #3 (Hold). Stocks such as Biogen Idec Inc. ( BIIB ), Jazz Pharmaceuticals Public Limited Company ( JAZZ ) and Santarus, Inc. ( SNTS ) appear to be more favorably placed. All three companies carry a Zacks Rank #1 (Strong Buy).



BIOGEN IDEC INC (BIIB): Free Stock Analysis Report

CELGENE CORP (CELG): Free Stock Analysis Report

JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report

SANTARUS INC (SNTS): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: BIIB , CELG , JAZZ , SNTS

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

85,117,424
  • $6.78 ▲ 11.88%
77,261,576
  • $17.53 ▲ 1.56%
61,066,548
  • $6.90 ▲ 2.99%
56,847,340
  • $112.65 ▲ 2.96%
52,788,366
  • $7.78 ▲ 1.83%
50,761,300
  • $25.14 ▲ 2.91%
47,781,137
  • $45.35 ▲ 10.18%
45,664,809
  • $7.17 ▲ 2.14%
As of 12/18/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com